InnovAge Holding Corp. (NASDAQ:INNV – Free Report) – Stock analysts at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for shares of InnovAge in a report issued on Tuesday, November 5th. William Blair analyst J. Haase now forecasts that the company will earn $0.00 per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for InnovAge’s current full-year earnings is ($0.02) per share. William Blair also issued estimates for InnovAge’s Q4 2025 earnings at $0.00 EPS and FY2026 earnings at $0.06 EPS.
InnovAge (NASDAQ:INNV – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). InnovAge had a negative return on equity of 7.43% and a negative net margin of 2.79%. The firm had revenue of $205.14 million for the quarter, compared to analyst estimates of $203.35 million. During the same quarter in the previous year, the company posted ($0.08) EPS.
Check Out Our Latest Report on InnovAge
InnovAge Trading Up 3.8 %
NASDAQ INNV opened at $6.30 on Thursday. The business’s 50-day moving average price is $5.93 and its two-hundred day moving average price is $5.37. InnovAge has a 12 month low of $3.52 and a 12 month high of $6.69. The firm has a market capitalization of $853.65 million, a PE ratio of -39.38 and a beta of 0.39. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 0.27.
Insider Buying and Selling at InnovAge
In other InnovAge news, insider Nicole Damato sold 4,372 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $5.95, for a total transaction of $26,013.40. Following the completion of the transaction, the insider now directly owns 240,795 shares of the company’s stock, valued at approximately $1,432,730.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.40% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On InnovAge
Large investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in shares of InnovAge by 7.0% in the second quarter. Rhumbline Advisers now owns 27,503 shares of the company’s stock worth $136,000 after acquiring an additional 1,793 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of InnovAge by 27.1% in the second quarter. Bank of New York Mellon Corp now owns 58,322 shares of the company’s stock worth $289,000 after acquiring an additional 12,448 shares during the period. Accordant Advisory Group Inc bought a new position in shares of InnovAge in the second quarter worth $496,000. Renaissance Technologies LLC boosted its holdings in shares of InnovAge by 3.1% in the second quarter. Renaissance Technologies LLC now owns 136,400 shares of the company’s stock worth $677,000 after acquiring an additional 4,100 shares during the period. Finally, Kent Lake Capital LLC boosted its holdings in shares of InnovAge by 3.7% in the first quarter. Kent Lake Capital LLC now owns 1,750,000 shares of the company’s stock worth $7,770,000 after acquiring an additional 62,141 shares during the period. 12.26% of the stock is owned by institutional investors.
InnovAge Company Profile
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management.
Featured Stories
- Five stocks we like better than InnovAge
- How to Evaluate a Stock Before Buying
- Monster Beverage Is a Scary Good Deal at Current Levels
- Profitably Trade Stocks at 52-Week Highs
- 2 Online Educational Platforms Staging a Turnaround
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Top 3 Sectors Outperforming After Trump’s Victory
Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.